Developer docs
API playgroundTry for free, no card

Search company profiles

PolyActiva

Full company profile

uuid0000ggx

Namestring
PolyActiva
Legal namestring
PolyActiva Pty Ltd
Websiteurl
polyactiva.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

PolyActiva Pty Ltd is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, with a U.S. operations office in Fort Worth, Texas. The company develops biodegradable ocular implants using its proprietary PREZIA™ Sustained Drug Delivery Technology platform, a polymeric prodrug system that chemically attaches a drug to a carrier polymer to enable site-specific, controlled drug delivery to the eye for periods ranging from one week to twelve months. Its product portfolio targets ophthalmic diseases where poor patient compliance with daily eye drops or the burden of frequent intravitreal injections limits clinical outcomes. Lead asset PA5108 is a six-month sustained-release Latanoprost Acid intracameral implant for open-angle glaucoma and ocular hypertension, currently in Phase 2b trials in the U.S. (NCT06964191). PA5346 is a second-generation 12-month Latanoprost Acid implant in Phase I, PA5691 is a Dexamethasone intravitreal implant for Diabetic Macular Edema in pre-clinical development, and an undisclosed fourth program for inherited retinal diseases is being co-developed with RareSight Inc.

PolyActiva is pre-revenue: products are investigational and not approved by FDA, and the company's website carries an explicit disclaimer that products are not for sale in the U.S. The company has raised approximately AUD $50.7M to date, including a Series B of AUD $9.2M in February 2013, a AUD $1.5M CUREator Grant in May 2024, and a AUD $40M Series C in May 2025 co-led by the Australian National Reconstruction Fund and Brandon Capital. The Series C proceeds are allocated to Phase 2b and Phase 3 development of PA5108, broader pipeline expansion using the PREZIA platform, and U.S. commercial preparation.

The go-to-market model, once products are approved, is enterprise field sales to ophthalmologists and eye care professionals for in-office administration of the micro-implants. The intellectual property estate covers eight active patent families comprising more than 160 granted patents and 17 pending applications across major jurisdictions, with four families and 60 granted patents specifically protecting the glaucoma program. The company was founded in 2010 (some sources cite 2009) and operates with 11-50 employees under a leadership team that was substantially refreshed in mid-2025 to add U.S. biopharma commercial experience ahead of late-stage clinical development and U.S. market entry.

Short descriptiontext

PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants using its proprietary PREZIA™ polymeric prodrug platform, targeting glaucoma, diabetic macular edema, and rare retinal diseases through single-administration sustained drug delivery lasting up to 12 months.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ocular drug delivery, biodegradable implants, ophthalmic pharmaceuticals, sustained release drugs, glaucoma treatments
Industry4 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Ophthalmic Goods Manufacturing339115
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ocular Drug Delivery / Ophthalmic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Ocular Drug Delivery Implants
TypeOne Time License
Description

PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants. Revenue will be generated from the sale of prescription drug products (PA5108, PA5346, PA5691) for ophthalmic diseases such as glaucoma and diabetic macular edema. Products are not yet approved or commercialized.

polyactiva.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1PREZIA™
Description

Proprietary sustained drug delivery technology platform for precise and controlled drug delivery to the eye, enabling biodegradable ocular implants

polyactiva.com
Core offering1 text field

PolyActiva develops and is preparing to commercialize a portfolio of biodegradable ocular micro-implants that deliver sustained, controlled doses of ophthalmic drugs directly into the eye for periods of 1 week to 12 months. The lead candidate, PA5108, is a 6-month Latanoprost Acid implant for open-angle glaucoma and ocular hypertension currently in Phase 2b trials, with a 12-month second-generation implant (PA5346) and a Dexamethasone intravitreal implant (PA5691) in earlier development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 26-35% clinically meaningful IOP reduction over 48-week treatment period
+3 more records
Product overview1 text field

PolyActiva is a clinical-stage biopharmaceutical company developing a portfolio of biodegradable ocular implants based on its proprietary PREZIA™ sustained drug delivery technology platform. The platform uses polymeric prodrug conjugates to enable site-specific, precise, and controlled drug delivery to the eye. The lead product, PA5108, is a 6-month Latanoprost Acid implant for glaucoma currently in Phase IIb trials. PA5346 is a second-generation 12-month implant in Phase I. PA5691 is a Dexamethasone implant for Diabetic Macular Edema in pre-clinical development. A fourth undisclosed program for inherited retinal diseases is being developed in partnership with RareSight Inc.

Product and service4 records
1PA5108 Latanoprost Acid Ocular Micro-Implant
CategoryOcular Drug Delivery Implant
Description

6-month sustained release intracameral ocular micro-implant delivering Latanoprost Acid directly into the eye for reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Administered in ophthalmologists' offices; fully biodegradable; no implant movement after administration. Phase 2 data showed 26–35% IOP reduction sustained over 48 weeks, with 94% of patients not requiring additional drop therapy.

2PA5346 Latanoprost Acid Ocular Micro-Implant (12-month)
CategoryOcular Drug Delivery Implant
Description

Second-generation 12-month sustained release Latanoprost Acid ocular micro-implant for extended dosing in a single administration for glaucoma and ocular hypertension patients. Currently in Phase I clinical trial.

3PA5691 Dexamethasone Intravitreal Implant
CategoryOcular Drug Delivery Implant
Description

Micro ocular implant delivered intravitreally for controlled, sustained release of Dexamethasone for back-of-eye diseases such as Diabetic Macular Edema (DME). Currently in pre-clinical stage.

4PolyActiva Rare Pediatric Retinal Disease Program (with RareSight Inc.)
CategoryOcular Drug Delivery Implant
Description

Undisclosed sustained release implant for inherited retinal disease, co-developed with RareSight Inc. for rare pediatric retinal diseases using the PREZIA platform. Currently in pre-clinical development.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases using PolyActiva's PREZIA™ platform. The joint effort aims to create long-acting, intravitreally administered treatments for inherited retinal disorders that currently lack approved drug options. Partnership leverages PolyActiva's proprietary platform to offer first-of-its-kind, NCE-eligible pro-drug candidates.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets ILUVIEN, a sustained-release intravitreal fluocinolone acetonide implant for DME, directly comparable to PolyActiva's PA5691 (Dexamethasone implant for DME).

TypeBroad incumbent
Description

Major ophthalmic pharmaceutical incumbent that markets XIPERE (suprachoroidal triamcinolone) and a broad portfolio competing with PolyActiva across multiple ocular indications.

TypeDirect peer
Description

Glaukos developed iDose TR, an intracameral sustained-release bimatoprost implant for glaucoma, the most direct competitor to PolyActiva's PA5108 in the sustained-release glaucoma space.

TypeBroad incumbent
Description

Markets DURYSTA, the first FDA-approved sustained-release bimatoprost implant for glaucoma. As a global pharmaceutical incumbent, it competes with PolyActiva across ophthalmology with broader resources and commercial reach.

TypeDirect peer
Description

Develops sustained-release ocular implants including DEXTENZA (dexamethasone intracanalicular insert) and OTX-TIC (travoprost intracameral implant), directly comparable to PolyActiva's PREZIA platform in mechanism and ophthalmic indications.

TypeDirect peer
Description

Specializes in sustained-release ocular drug delivery using bioerodible Durasert and Verisome technologies, competing directly with PolyActiva in back-of-eye and anterior segment indications including DME.

7Santen Pharmaceutical
TypeBroad incumbent
Description

Japanese specialty ophthalmology company and prior employer of PolyActiva's CEO; competes broadly in glaucoma therapeutics and is a likely strategic acquirer of companies like PolyActiva.

TypeBroad incumbent
Description

European ophthalmology specialty company developing novel therapeutics for glaucoma and other ocular conditions, including sustained-release approaches, with overlapping investor and personnel networks with PolyActiva.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing novel therapeutics for retinal diseases, partially overlapping with PolyActiva's PA5691 and rare retinal disease programs.

TypeEmerging player
Description

Clinical-stage ophthalmic company with proprietary mucus-penetrating particle technology, focused on rare ocular conditions including rare orphan retinal indications that overlap with PolyActiva's rare disease strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PolyActiva

Ocular Drug Delivery / Ophthalmic Pharmaceuticalspolyactiva.com

PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants using its proprietary PREZIA™ polymeric prodrug platform, targeting glaucoma, diabetic macular edema, and rare retinal diseases through single-administration sustained drug delivery lasting up to 12 months.

What PolyActiva does

PolyActiva Pty Ltd is a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, with a U.S. operations office in Fort Worth, Texas. The company develops biodegradable ocular implants using its proprietary PREZIA™ Sustained Drug Delivery Technology platform, a polymeric prodrug system that chemically attaches a drug to a carrier polymer to enable site-specific, controlled drug delivery to the eye for periods ranging from one week to twelve months. Its product portfolio targets ophthalmic diseases where poor patient compliance with daily eye drops or the burden of frequent intravitreal injections limits clinical outcomes. Lead asset PA5108 is a six-month sustained-release Latanoprost Acid intracameral implant for open-angle glaucoma and ocular hypertension, currently in Phase 2b trials in the U.S. (NCT06964191). PA5346 is a second-generation 12-month Latanoprost Acid implant in Phase I, PA5691 is a Dexamethasone intravitreal implant for Diabetic Macular Edema in pre-clinical development, and an undisclosed fourth program for inherited retinal diseases is being co-developed with RareSight Inc.

PolyActiva is pre-revenue: products are investigational and not approved by FDA, and the company's website carries an explicit disclaimer that products are not for sale in the U.S. The company has raised approximately AUD $50.7M to date, including a Series B of AUD $9.2M in February 2013, a AUD $1.5M CUREator Grant in May 2024, and a AUD $40M Series C in May 2025 co-led by the Australian National Reconstruction Fund and Brandon Capital. The Series C proceeds are allocated to Phase 2b and Phase 3 development of PA5108, broader pipeline expansion using the PREZIA platform, and U.S. commercial preparation.

The go-to-market model, once products are approved, is enterprise field sales to ophthalmologists and eye care professionals for in-office administration of the micro-implants. The intellectual property estate covers eight active patent families comprising more than 160 granted patents and 17 pending applications across major jurisdictions, with four families and 60 granted patents specifically protecting the glaucoma program. The company was founded in 2010 (some sources cite 2009) and operates with 11-50 employees under a leadership team that was substantially refreshed in mid-2025 to add U.S. biopharma commercial experience ahead of late-stage clinical development and U.S. market entry.

PolyActiva firmographics

Firmographics
Name
PolyActiva
Legal name
PolyActiva Pty Ltd
Website
https://polyactiva.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants using its proprietary PREZIA™ polymeric prodrug platform, targeting glaucoma, diabetic macular edema, and rare retinal diseases through single-administration sustained drug delivery lasting up to 12 months.
Ownership category
akta.pro rank

PolyActiva industry classification

Industry
Product category
Ocular Drug Delivery / Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAJAI
Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Ocular drug delivery
  • Biodegradable implants
  • Ophthalmic pharmaceuticals
  • Sustained release drugs
  • Glaucoma treatments

Where PolyActiva is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

PolyActiva business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Ocular Drug Delivery Implants: PolyActiva is a clinical-stage biopharmaceutical company developing biodegradable ocular implants. Revenue will be generated from the sale of prescription drug products (PA5108, PA5346, PA5691) for ophthalmic diseases such as glaucoma and diabetic macular edema. Products are not yet approved or commercialized.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

PolyActiva product offering

Product offering

Core offering

PolyActiva develops and is preparing to commercialize a portfolio of biodegradable ocular micro-implants that deliver sustained, controlled doses of ophthalmic drugs directly into the eye for periods of 1 week to 12 months. The lead candidate, PA5108, is a 6-month Latanoprost Acid implant for open-angle glaucoma and ocular hypertension currently in Phase 2b trials, with a 12-month second-generation implant (PA5346) and a Dexamethasone intravitreal implant (PA5691) in earlier development.

Product overview

PolyActiva is a clinical-stage biopharmaceutical company developing a portfolio of biodegradable ocular implants based on its proprietary PREZIA™ sustained drug delivery technology platform. The platform uses polymeric prodrug conjugates to enable site-specific, precise, and controlled drug delivery to the eye. The lead product, PA5108, is a 6-month Latanoprost Acid implant for glaucoma currently in Phase IIb trials. PA5346 is a second-generation 12-month implant in Phase I. PA5691 is a Dexamethasone implant for Diabetic Macular Edema in pre-clinical development. A fourth undisclosed program for inherited retinal diseases is being developed in partnership with RareSight Inc.

Differentiator

Problem solved

Functional benefit

Brands

  • PREZIA™: Proprietary sustained drug delivery technology platform for precise and controlled drug delivery to the eye, enabling biodegradable ocular implants

Products and services

  • PA5108 Latanoprost Acid Ocular Micro-Implant 6-month sustained release intracameral ocular micro-implant delivering Latanoprost Acid directly into the eye for reduction of intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Administered in ophthalmologists' offices; fully biodegradable; no implant movement after administration. Phase 2 data showed 26–35% IOP reduction sustained over 48 weeks, with 94% of patients not requiring additional drop therapy.
  • PA5346 Latanoprost Acid Ocular Micro-Implant (12-month) Second-generation 12-month sustained release Latanoprost Acid ocular micro-implant for extended dosing in a single administration for glaucoma and ocular hypertension patients. Currently in Phase I clinical trial.
  • PA5691 Dexamethasone Intravitreal Implant Micro ocular implant delivered intravitreally for controlled, sustained release of Dexamethasone for back-of-eye diseases such as Diabetic Macular Edema (DME). Currently in pre-clinical stage.
  • PolyActiva Rare Pediatric Retinal Disease Program (with RareSight Inc.) Undisclosed sustained release implant for inherited retinal disease, co-developed with RareSight Inc. for rare pediatric retinal diseases using the PREZIA platform. Currently in pre-clinical development.

Quantifiable outcome

  • 26-35% clinically meaningful IOP reduction over 48-week treatment period
  • +3 more outcomes

Companies that use PolyActiva

Customer profile

Segments2 records

Ideal customer profiles2 records

PolyActiva technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

PolyActiva partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • RareSight Inc.coreStrategic or Co-development Partner · 5 November 2025Strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases using PolyActiva's PREZIA™ platform. The joint effort aims to create long-acting, intravitreally administered treatments for inherited retinal disorders that currently lack approved drug options. Partnership leverages PolyActiva's proprietary platform to offer first-of-its-kind, NCE-eligible pro-drug candidates.

Scale indicators6 records

Recent moves2 records

Expansion highlights6 records

PolyActiva competitors and assessment

Company assessment

Direct peers

  • Alimera Sciences: Markets ILUVIEN, a sustained-release intravitreal fluocinolone acetonide implant for DME, directly comparable to PolyActiva's PA5691 (Dexamethasone implant for DME).
  • Glaukos Corporation: Glaukos developed iDose TR, an intracameral sustained-release bimatoprost implant for glaucoma, the most direct competitor to PolyActiva's PA5108 in the sustained-release glaucoma space.
  • Ocular Therapeutix: Develops sustained-release ocular implants including DEXTENZA (dexamethasone intracanalicular insert) and OTX-TIC (travoprost intracameral implant), directly comparable to PolyActiva's PREZIA platform in mechanism and ophthalmic indications.
  • EyePoint Pharmaceuticals: Specializes in sustained-release ocular drug delivery using bioerodible Durasert and Verisome technologies, competing directly with PolyActiva in back-of-eye and anterior segment indications including DME.

Broad incumbents

  • Bausch + Lomb: Major ophthalmic pharmaceutical incumbent that markets XIPERE (suprachoroidal triamcinolone) and a broad portfolio competing with PolyActiva across multiple ocular indications.
  • AbbVie (Allergan Aesthetics/Eye Care): Markets DURYSTA, the first FDA-approved sustained-release bimatoprost implant for glaucoma. As a global pharmaceutical incumbent, it competes with PolyActiva across ophthalmology with broader resources and commercial reach.
  • Santen Pharmaceutical: Japanese specialty ophthalmology company and prior employer of PolyActiva's CEO; competes broadly in glaucoma therapeutics and is a likely strategic acquirer of companies like PolyActiva.
  • Nicox: European ophthalmology specialty company developing novel therapeutics for glaucoma and other ocular conditions, including sustained-release approaches, with overlapping investor and personnel networks with PolyActiva.

Emerging players

  • Kodiak Sciences: Clinical-stage biopharmaceutical company developing novel therapeutics for retinal diseases, partially overlapping with PolyActiva's PA5691 and rare retinal disease programs.
  • Kala Bio: Clinical-stage ophthalmic company with proprietary mucus-penetrating particle technology, focused on rare ocular conditions including rare orphan retinal indications that overlap with PolyActiva's rare disease strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PolyActiva social profiles

Digital presence

PolyActiva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PolyActiva leadership team

Management profile

Number of profiles

Profiles13 records

PolyActiva funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PolyActiva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PolyActiva

What does PolyActiva do?

PolyActiva develops and is preparing to commercialize a portfolio of biodegradable ocular micro-implants that deliver sustained, controlled doses of ophthalmic drugs directly into the eye for periods of 1 week to 12 months. The lead candidate, PA5108, is a 6-month Latanoprost Acid implant for open-angle glaucoma and ocular hypertension currently in Phase 2b trials, with a 12-month second-generation implant (PA5346) and a Dexamethasone intravitreal implant (PA5691) in earlier development.

Is PolyActiva a public or private company?

PolyActiva is a private company. It is classified as venture growth investor backed and is currently operating.

When was PolyActiva founded?

PolyActiva was founded in 2010. It employs 11 to 50 people.

Where is PolyActiva based?

PolyActiva is headquartered in Melbourne, Australia, in the Oceania region.

How does PolyActiva make money?

One revenue line is on record: ocular Drug Delivery Implants.

Who are PolyActiva's main competitors?

Direct peers on record are Alimera Sciences, Glaukos Corporation, Ocular Therapeutix and EyePoint Pharmaceuticals. Broad incumbents are Bausch + Lomb, AbbVie (Allergan Aesthetics/Eye Care), Santen Pharmaceutical and Nicox. Emerging players are Kodiak Sciences and Kala Bio.

Does PolyActiva have an API?

No public API is recorded for PolyActiva.

What industry is PolyActiva in?

PolyActiva's product category is Ocular Drug Delivery / Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal DiseasesPolyActiva and RareSight, Inc. announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases using PolyActiva's proprietary PREZIA™ drug delivery platform, with the goal of creating the first-ever approved drug treatments for inherited retinal diseases that currently have no pharmacologic options. The collaboration combines RareSight's therapeutic discovery expertise with PolyActiva's sustained-release pro-drug technology, administered intravitreally to deliver zero-order treatment directly to the retina without requiring patient administration. Both companies aim to address early-onset vision loss in children, a population that has been largely overlooked, with therapies that could potentially change patients' lives.BioSpacePolyActiva to Present Advancements in Next-Generation Ocular Micro-Implant Technology at Eyecelerator® @ AAO 2025PolyActiva, a clinical-stage biopharmaceutical company headquartered in Melbourne, Australia, announced that its Chief Scientific Officer will present at the Eyecelerator @ AAO 2025 Annual Meeting on October 16, 2025, in Orlando, Florida, highlighting the company's PREZIA drug delivery platform and recent clinical milestones. The company reported successful Phase 2a clinical trial results for its PA5108 ocular micro-implant for glaucoma, demonstrating consistent and significant reductions in intraocular pressure over two 21-week treatment cycles with no adverse impact on corneal endothelium. PolyActiva has initiated a U.S. Phase 2b clinical trial of PA5108 that is actively enrolling patients across 12 U.S. clinical sites, designed to evaluate two implant doses ahead of a planned Phase 3 registration program.Dallas InnovatesAustralia's PolyActiva Opens Fort Worth Office With New Locally Based CEO, CFO, and CSOAustralian biopharmaceutical company PolyActiva has opened a new office in Fort Worth, USA, appointing Jerry St. Peter as CEO along with new CFO Wes Brazell and CSO Michael Brubaker to lead its U.S. clinical trials for glaucoma treatment PA5108. This leadership expansion follows a $25 million Series C funding round led by an Australian Sovereign Wealth Fund, aiming to advance the drug into Phase 2b trials. The new executives bring prior experience from Eyevance Pharmaceuticals, which was acquired by Santen, indicating strategic continuity in ophthalmic drug development.The Pharma LetterPolyActiva raises $25 million and appoints new CEO to steer US expansionAustralian biotech company PolyActiva has appointed Jerry St Peter as its new chief executive to lead its commercialization efforts in the United States. This leadership change coincides with a $25 million financing round aimed at supporting the expansion of its lead eye implant therapy.citybizPolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series CPolyActiva appointed Jerry St. Peter as CEO and closed a $25M Series C led by an Australian sovereign wealth fund. The funding supports late-stage development of its lead product PA5108, a biodegradable ocular implant for glaucoma, with a Phase 2b study starting in Q3 2025.Fastdata极数澳大利亚开创性生物技术服务商PolyActiva获得4000万澳元C轮融资 – Fastdata极数PolyActiva, an Australian biotechnology service provider, raised 40 million AUD in Series C funding from NRFC and Brandon Capital Partners. The company develops drug-polymer conjugates using a scalable manufacturing process that adapts to existing equipment. It is now developing its first products.BrandoncapitalPolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug DeliveryPolyActiva, a biopharmaceutical company developing drug delivery technology, secured AUD $40 million in Series C funding to advance its PRESIA™ platform and clinical candidate PA5108, a biodegradable implant for glaucoma treatment. The funding will support ongoing clinical trials, including a Phase 2b and a potential Phase 3 study, and broader development of its pipeline.PR NewswirePolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month periodPolyActiva Pty Ltd announced successful completion of its Phase I clinical study for the Latanoprost FA SR Ocular Implant, with all 8 patients tolerating the device and no significant safety findings reported. The implant provides sustained latanoprost delivery over six months before biodegrading completely, offering a potential replacement for daily eye drop therapy that addresses the adherence problem affecting up to 46 percent of glaucoma patients. The company has now initiated a Phase II dose-ranging study at nine clinical trial sites in Australia following this initial success.PR Newswire APACPolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of DirectorsPolyActiva appointed Tracy Valorie, former Bausch + Lomb executive, to its board. She previously led ophthalmology at Pfizer and Bausch + Lomb. The company is advancing two ophthalmic implants into clinical trials, including a glaucoma implant.